Clinical Trial

Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC

Study acronym: NeoTRACT
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will assess if the presence of immune system cells in and around the tumor impacts tumor shrinkage in patients receiving neoadjuvant chemoimmunotherapy for triple-negative breast cancer.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-12-01; most recent amendment 2026-04-27.
Status change: Recruiting → Active, Not Recruiting 2026-04-27
Status change: Not Yet Recruiting → Recruiting 2023-01-26
Trial Details
NCT Number NCT05645380
Lead Sponsor University of Kansas Medical Center
Conditions Triple Negative Breast Cancer, Breast Cancer
Enrollment 139 participants
Start Date 2022-12-05
Primary Completion 2026-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-28